Lumida
/GERN
⌘K
Geron Corp

Geron Corp

GERN
$1.35USD↓-1.46%-0.02 today

MARKET CAP

867.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$2

AI Summary

Stalk
Sell NowMedium

GERN has decisively broken key support and entered a Stage 3 distribution phase, with price now below declining EMAs and showing no sign of exhaustion despite extreme oversold readings. The active Support Failure pattern underscores supply dominance and further downside potential. Medium‐term bias remains bearish, and short‐term momentum favors selling now to capture the breakdown continuation before any relief rally into the broken EMA zone.

  • ↑Q2 net revenue of $57.5M drove 17% YoY and 11% QoQ growth
  • ↑Raised full-year 2026 guidance to $220–240M on continued demand
  • ↓Low earnings yield and weak book‐to‐price metrics suggest overvaluation
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Geron Corporation (NASDAQ: GERN) is a clinical-stage biopharmaceutical company focusing on developing and commercializing innovative treatments for hematologic malignancies, primarily its leading product Rytelo (imetelstat), a telomerase inhibitor targeting low-risk myelodysplastic syndromes (MDS). With a strong cash position and ongoing investments in commercialization, Geron is in a competitive sector, navigating collaborative strategies within the hematology field while targeting both the U.S. and European markets for its therapies.

Bull says

  • ↑Q2 net revenue of $57.5M drove 17% YoY and 11% QoQ growth
  • ↑Raised full-year 2026 guidance to $220–240M on continued demand
  • ↑Strong cash position of $327M funds Rytelo commercialization
  • ↑Institutional ownership is high, boosting investor confidence
  • ↑Stock jumped 21.6% post‐earnings and holds 13.95% two‐week gain
  • ↑European market launch plans expand patient addressable base

Bear says

  • ↓Low earnings yield and weak book‐to‐price metrics suggest overvaluation
  • ↓Profitability remains challenged with ongoing operating losses
  • ↓Short interest of 9.85% highlights bearish market sentiment
  • ↓FDA trial design discussions pose regulatory approval risk
  • ↓Competitive hematology landscape may slow Rytelo adoption
  • ↓High volatility and negative growth factors could pressure shares

Investment themes with GERN

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-08-2025bullish

Transcript signals

Bull points

  • we are very pleased with the committee's decision to recognize the positive clinical benefit risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS.
  • We believe that we are positioned very well for commercial value creation and are well prepared to execute a successful U.S. launch upon potential approval.
  • We also have commercial supply arrangements in place and have finalized our specialty distribution network and third-party logistics.

Bear points

  • Total operating expenses for the first quarter of 2024 were $56.4 million compared to $40.1 million for the same period in 2023.
  • Research and development expenses for the first quarter of 2024 were $29.4 million compared to $27.2 million for the same period in 2023.
Read full transcript analysis ›